Vertex Pharma stock pre-market at EUR 445.50
Published on 10/19/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and trading levels
- Vertex Pharmaceuticals is scheduled to report third-quarter results on November 2, 2026.
- Vertex Pharma stock trades pre-market at EUR 445.50 at 7:51 a.m. CEST at Lang & Schwarz on October 19, 2026.
- The earnings call is scheduled for 4:30 p.m. ET on November 2, 2026.
Vertex Pharma stock trades pre-market at EUR 445.50 at Lang & Schwarz at 7:51 a.m. CEST on October 19, 2026. The bid was EUR 443.00 and the ask was EUR 448.00. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
What matters today
Vertex Pharmaceuticals is scheduled to report its third-quarter 2026 financial results on November 2, 2026, after the financial markets close, according to its investor-relations release. A move to the round-number level of EUR 450.00 would represent a distance of 1.01 percent from the pre-market price. The company said its conference call and webcast are scheduled for 4:30 p.m. ET on November 2, 2026, with international and U.S. dial-in access detailed in the release.
Vertex Pharmaceuticals is a biotechnology company with approved therapies and investigational programs across serious diseases, including cystic fibrosis, sickle cell disease, acute pain and kidney disease.
Market context: Market report S&P 500.
